SHANGHAI, Aug. 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its senior management will be participating in the following upcoming conferences in September 2011:

Mr. Michael Hui, founder and Chief Executive Officer of ShangPharma, and William Dai, Chief Financial Officer, will be presenting at the following conferences in New York City and Boston: 


    --  Morgan Stanley Global Healthcare Unplugged Conference
       September 13-14, 2011
       New York City, NY

    --  Morgan Stanley China Global Healthcare Day
       September 15, 2011
       Boston, MA

    --  UBS Global Life Sciences Conference
       September 19-21, 2011
       New York City, NY

Ms. Lan Xie, Vice President of Finance and Investor Relations of ShangPharma, will be presenting at the following conference in London:


                            -- Jefferies London Healthcare Conference
     September 27-28, 2011
     London, United Kingdom

Presentation materials will be available under the Presentation section of the Company's investor relations website at http://ir.shangpharma.com.

About ShangPharma Corporation

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. 


    For further information, please contact:

    ShangPharma Corporation

    In Shanghai, China
    Ms. Lan Xie
    VP of Finance and Investor Relations
    Email: IR@shangpharma.com

    Christensen

    In New York:
    Kimberly Minarovich
    Tel: +1 917-533-3268
    Email: kminarovich@christensenir.com

    In Hong Kong:
    Tip Fleming
    Tel: +852-9212-0684
    Email: tfleming@christensenir.com

SOURCE ShangPharma Corporation